Warfarin initiation and monitoring with clotting factors II, VII, and X
- PMID: 14742761
- DOI: 10.1345/aph.1D266
Warfarin initiation and monitoring with clotting factors II, VII, and X
Abstract
Objective: To report a case of a patient with antiphospholipid antibody syndrome and multiple thromboses who developed heparin-induced thrombocytopenia (HIT) and subsequent international normalized ratio (INR) prolongation possibly due to antiphospholipid antibodies.
Case summary: A 56-year-old white woman with a history of antiphospholipid antibody syndrome and thrombosis taking chronic warfarin was admitted for gastrointestinal concerns and found to have an INR >14. Warfarin was discontinued, vitamin K was administered, and a heparin infusion was initiated. Over the next 2 days, thrombocytopenia, hypotension, tachycardia, hyponatremia, and progressive abdominal pain developed. Upon transfer to a tertiary care center, HIT was diagnosed, and a lepirudin infusion was initiated. Subsequently, a sudden elevation of the INR occurred (>14) with low prothrombin (factor II) activity. After INR values declined to 2-3, warfarin was reinitiated with dosing adjusted using factor X and II activity levels. Clotting factors II and X activities were measured to monitor long-term warfarin therapy, with no evidence of complications after 7 months.
Discussion: Typically, the INR is used to assess the intensity of anticoagulation. The INR value represents the reduction of clotting factors II, VII, and X. In rare circumstances, an independent inhibitor or interfering substance can interfere with the process of measuring the INR. In such situations, an alternative approach can be direct measurement of clotting factor concentrations.
Conclusions: Factor II and/or factor X activity levels provided an alternative means for measuring the anticoagulant effects of warfarin in the presence of a significant inhibitor (antiphospholipid antibodies) that biased the INR measurements.
Similar articles
-
Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination.J Thromb Thrombolysis. 2000 Apr;9(3):263-9. doi: 10.1023/a:1018722829498. J Thromb Thrombolysis. 2000. PMID: 10728026
-
Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy.Biomed Pharmacother. 2010 Feb;64(2):130-2. doi: 10.1016/j.biopha.2009.09.020. Epub 2009 Dec 16. Biomed Pharmacother. 2010. PMID: 20045627 Clinical Trial.
-
Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.Haematologica. 2002 Oct;87(10):1074-80. Haematologica. 2002. PMID: 12368163
-
Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?Acta Clin Croat. 2010 Dec;49(4):469-77. Acta Clin Croat. 2010. PMID: 21830460 Review.
-
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.Curr Opin Investig Drugs. 2002 Aug;3(8):1171-80. Curr Opin Investig Drugs. 2002. PMID: 12211410 Review.
Cited by
-
An Acute Need Inspiration: Autoneutralization of Lupus Anticoagulants in Affected Prothrombin Times (PT) and Activated Partial Thromboplastin Times (APTT).Methods Mol Biol. 2023;2663:289-295. doi: 10.1007/978-1-0716-3175-1_18. Methods Mol Biol. 2023. PMID: 37204718
-
Chromogenic Factor X Assay for Monitoring Warfarin Anticoagulation in a Child With a Prosthetic Mitral Valve.Mayo Clin Proc Innov Qual Outcomes. 2021 Aug 10;5(5):811-816. doi: 10.1016/j.mayocpiqo.2021.07.001. eCollection 2021 Oct. Mayo Clin Proc Innov Qual Outcomes. 2021. PMID: 34430797 Free PMC article.
-
Hemostasis and Thrombosis: An Overview Focusing on Associated Laboratory Testing to Diagnose and Help Manage Related Disorders.Methods Mol Biol. 2023;2663:3-38. doi: 10.1007/978-1-0716-3175-1_1. Methods Mol Biol. 2023. PMID: 37204701 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical